Anti-adhesion molecules: Is gut specificity the key for a good safety profile?

Current Drug Delivery

Volumn 9, Issue 4, 2012, Pages 333-337

  Allen, Patrick B ^a  

^a NORTHERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

Author keywords

Adalimumab; Alicaforsen; Anti TNF; Crohn's disease; Inflammatory bowel disease; Infliximab; Natalizumab; Ulcerative colitis; Vedolizumab

Indexed keywords

ALICAFORSEN; BETA1A INTERFERON; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; NATALIZUMAB; VEDOLIZUMAB;

ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG WITHDRAWAL; ENTERITIS; HERPES SIMPLEX; HUMAN; HYPERSENSITIVITY REACTION; LEUKOCYTE COUNT; LOBAR PNEUMONIA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL ADHESION MOLECULES; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES;

EID: 84863557933     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. D'Haens, G.; Baert, F.; van Assche, G.; Caenepeel, P.; Vergauwe, P.; Tuynman, H.; De Vos, M.; van Deventer, S.; Stitt, L.; Donner, A.; Vermeire, S.; Van de Mierop, F. J.; Coche, J. C.; van der Woude, J.; Ochsenkuhn, T.; van Bodegraven, A. A.; Van Hootegem, P. P.; Lambrecht, G. L.; Mana, F.; Rutgeerts, P.; Feagan, B. G.; Hommes, D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet, 2008, 371(9613), 660-667.
2. Regueiro, M.; Schraut, W.; Baidoo, L.; Kip, K. E.; Sepulveda, A. R.; Pesci, M.; Harrison, J.; Plevy, S. E. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology, 2009, 136 (2), 441-450 e1; quiz 716.
3. Sandborn, W. J.; Rutgeerts, P.; Feagan, B. G.; Reinisch, W.; Olson, A.; Johanns, J.; Lu, J.; Horgan, K.; Rachmilewitz, D.; Hanauer, S. B.; Lichtenstein, G. R.; de Villiers, W. J.; Present, D.; Sands, B. E.; Colombel, J. F. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology, 2009, 137(4), 1250.
4. Colombel, J. F.; Sandborn, W. J.; Rutgeerts, P.; Enns, R.; Hanauer, S. B.; Panaccione, R.; Schreiber, S.; Byczkowski, D.; Li, J.; Kent, J. D.; Pollack, P. F. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology, 2007, 132 (1), 52-65.
5. Feagan, B. G.; Panaccione, R.; Sandborn, W. J.; D'Haens, G. R.; Schreiber, S.; Rutgeerts, P. J.; Loftus, E. V., Jr.; Lomax, K. G.; Yu, A. P.; Wu, E. Q.; Chao, J.; Mulani, P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology, 2008, 135 (5), 1493-1499.
6. Loftus, E. V.; Feagan, B. G.; Colombel, J. F.; Rubin, D. T.; Wu, E. Q.; Yu, A. P.; Pollack, P. F.; Chao, J.; Mulani, P. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am. J. Gastroenterol., 2008, 103 (12), 3132-3141.
7. Sandborn, W. J.; Lichtenstein, G. R.; Schreiber, S. The long-term, 30 months, efficacy and tolerability of certolizumab pegol therapy for Crohn's disease. Am. J. Gastroenterol., 2008, 103, 1099.
8. Regueiro, M.; Siemanowski, B.; Kip, K. E.; Plevy, S. Infliximab dose intensification in Crohn's disease. Inflamm. Bowel. Dis., 2007, 13 (9), 1093-1099.
9. Hanauer, S. B.; Feagan, B. G.; Lichtenstein, G. R.; Mayer, L. F.; Schreiber, S.; Colombel, J. F.; Rachmilewitz, D.; Wolf, D. C.; Olson, A.; Bao, W.; Rutgeerts, P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002, 359 (9317), 1541-1549.
10. Hyams, J.; Crandall, W.; Kugathasan, S.; Griffiths, A.; Olson, A.; Johanns, J.; Liu, G.; Travers, S.; Heuschkel, R.; Markowitz, J.; Cohen, S.; Winter, H.; Veereman- Wauters, G.; Ferry, G.; Baldassano, R. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology, 2007, 132 (3), 863-873; quiz 1165-6.
11. Hyams, J.; Crandall, W.; Kugathasan, S.; Griffiths, A.; Olson, A.; Johanns, J.; Liu, G.; Travers, S.; Heuschkel, R.; Markowitz, J.; Cohen, S.; Winter, H.; Veereman-Wauters, G.; Ferry, G.; Baldassano, R. Induction and maintenance iInfliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology, 2007, 132 (3), 863-873.
12. Rudolph, S.; Weinberg, D.; McCabe, R. Long-Term durability of Crohn's disease treatment with infliximab. Digest. Dis. Sci., 2008, 53 (4), 1033-1041.
13. Schnitzler, F., Fidder, H.; Ferrante, M. et al. Flexibility in interval and dosing of infliximab enables maintained response of patinets with Crohn's disease. Gastroenterology, 2008, 134 (Suppl 1), A658.
14. de Ridder, L.; Rings, E.H.H.M.; Damen, G.M.; Kneepkens, C.M.F.; Schweizer, J.J.; Kokke, F.T.M.; Benninga, M.A.; Norbruis, O.F.; Hoekstra, J.H.; Gijsbers, C.F.M.; Escher, J.C. Infliximab dependency in pediatric Crohn's disease: Long-term follow-up of an unselected cohort. Inflamm. Bowel. Dis., 2008, 14 (3), 353-358.
15. Farrell, R. J.; Alsahli, M.; Jeen, Y. T.; Falchuk, K. R.; Peppercorn, M. A.; Michetti, P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology, 2003, 124 (4), 917-924.
16. Gonzalez-Lama, Y.; Lopez-San Roman, A.; Marin-Jimenez, I.; Casis, B.; Vera, I.; Bermejo, F.; Perez-Calle, J. L.; Taxonera, C.; Martinez-Silva, F.; Menchen, L.; Martinez-Montiel, P.; Calvo, M.; Carneros, J. A.; Lopez, P.; Mendoza, J. L.; Milicua, J. M.; Huerta, A.; Sanchez, F.; Abreu, L.; Lopez-Palacios, N.; Mate, J.; Gisbert, J. P.; Group for the Study of Inflammatory Bowel Diseases from MADRID., Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterol. Hepatol., 2008, 31 (7), 421-426.
17. Hommes, D. W.; van de Heisteeg, B. H.; van der Spek, M.; Bartelsman, J. F.; van Deventer, S. J. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm. Bowel. Dis., 2002, 8 (2), 81-86.
18. Rutgeerts, P.; D'Haens, G.; Targan, S.; Vasiliauskas, E.; Hanauer, S. B.; Present, D. H.; Mayer, L.; Van Hogezand, R. A.; Braakman, T.; DeWoody, K. L.; Schaible, T. F.; Van Deventer, S. J. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology, 1999, 117 (4), 761-769.
19. Corman, S. I. M., Beaulieu, D.B. et al., Escalation of infliximab maintenance therapy in Crohn's disease. Am. J. Gastroenterol., 2006, 101, S470.
20. Gonzaga, J.E.; Ananthakrishnan, A.N.; Issa, M.; Beaulieu, D.B.; Skaros, S.; Zadvornova, Y.; Johnson, K.; Otterson, M.F.; Binion, D.G. Durability of infliximab in Crohn's disease patients treated with maintenance infusions beyond one year. Gastroenterology 2008, 134 (Suppl 1), A665.
21. Milestone, A.N.; Bullas, D.C.; Hart, A.L.; Kamm, M.A.; Arebi, N. Long-term outcome and adverse events in Crohn's disease patients treated with infliximab at a single tertiary referral center over 9 years. Gastroenterology, 2008, 134 (Suppl 1), A348.
22. Colombel, J.-F.; Sandborn, W. J.; Rutgeerts, P.; Enns, R.; Hanauer, S. B.; Panaccione, R.; Schreiber, S.; Byczkowski, D.; Li, J.; Kent, J. D.; Pollack, P. F. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM Trial. Gastroenterology, 2007, 132 (1), 52-65.
23. Schreiber, S.; Khaliq-Kareemi, M.; Lawrance, I. C.; Thomsen, O. O.; Hanauer, S. B.; McColm, J.; Bloomfield, R.; Sandborn, W. J.; the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab Pegol for Crohn's disease. N. Engl. J. Med., 2007, 357 (3), 239-250.
24. von Andrian, U. H.; Engelhardt, B. Alpha4 integrins as therapeutic targets in autoimmune disease. N. Engl. J. Med., 2003, 348 (1), 68-72.
25. Danese, S.; Semeraro, S.; Marini, M.; Roberto, I.; Armuzzi, A.; Papa, A.; Gasbarrini, A. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig. Liver Dis., 2005, 37 (11), 811-818.
26. Gordon, F. H.; Lai, C. W.; Hamilton, M. I.; Allison, M. C.; Srivastava, E. D.; Fouweather, M. G.; Donoghue, S.; Greenlees, C.; Subhani, J.; Amlot, P. L.; Pounder, R. E. A randomized placebocontrolled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology, 2001, 121 (2), 268-274.
27. Ghosh, S.; Goldin, E.; Gordon, F. H.; Malchow, H. A.; Rask-Madsen, J.; Rutgeerts, P.; Vyhnalek, P.; Zadorova, Z.; Palmer, T.; Donoghue, S. Natalizumab for active Crohn's disease. N. Engl. J. Med., 2003, 348 (1), 24-32.
28. Sandborn, W. J.; Colombel, J. F.; Enns, R.; Feagan, B. G.; Hanauer, S. B.; Lawrance, I. C.; Panaccione, R.; Sanders, M.; Schreiber, S.; Targan, S.; van Deventer, S.; Goldblum, R.; Despain, D.; Hogge, G. S.; Rutgeerts, P. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med., 2005, 353 (18), 1912-1925.
29. Feagan, B.; Hass, S.; Panjabi, S. The impact of quality of life of patients exposed to or failing anti-TNF therpay in the ENACT 2 trial. Gastroenterology, 2009, 136 (Suppl 1), S1059.
30. Targan, S. R.; Feagan, B. G.; Fedorak, R. N.; Lashner, B. A.; Panaccione, R.; Present, D. H.; Spehlmann, M. E.; Rutgeerts, P. J.; Tulassay, Z.; Volfova, M.; Wolf, D. C.; Hernandez, C.; Bornstein, J.; Sandborn, W. J. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology, 2007, 132 (5), 1672-1683.
31. Miller, D. H.; Khan, O. A.; Sheremata, W. A.; Blumhardt, L. D.; Rice, G. P.; Libonati, M. A.; Willmer-Hulme, A. J.; Dalton, C. M.; Miszkiel, K. A.; O'Connor, P. W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 2003, 348 (1), 15-23.
32. Tubridy, N.; Behan, P. O.; Capildeo, R.; Chaudhuri, A.; Forbes, R.; Hawkins, C. P.; Hughes, R. A.; Palace, J.; Sharrack, B.; Swingler, R.; Young, C.; Moseley, I. F.; MacManus, D. G.; Donoghue, S.; Miller, D. H. The effect of antialpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology, 1999, 53 (3), 466-472.
33. TYSABRI. Elan Pharamaceuticals. Inc. South San Francisco, 2008.
34. Rudick, R. A.; Stuart, W. H.; Calabresi, P. A.; Confavreux, C.; Galetta, S. L.; Radue, E. W.; Lublin, F. D.; Weinstock-Guttman, B.; Wynn, D. R.; Lynn, F.; Panzara, M. A.; Sandrock, A. W. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med.m 2006, 354 (9), 911-923.
35. Langer-Gould, A.; Atlas, S. W.; Green, A. J.; Bollen, A. W.; Pelletier, D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med., 2005, 353 (4), 375-381.
36. Kleinschmidt-DeMasters, B. K.; Tyler, K. L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med., 2005, 353 (4), 369-374.
37. Van Assche, G.; Van Ranst, M.; Sciot, R.; Dubois, B.; Vermeire, S.; Noman, M.; Verbeeck, J.; Geboes, K.; Robberecht, W.; Rutgeerts, P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med., 2005, 353 (4), 362-368.
38. Bozic, C. B.; Kim, R. et al. Natalizumab in patients with relapsing multiple sclerosis: updated utilization and saftey results including TOUCH and Tygris. American Academy of Neurology 61st Annual Meeting, Seattle, WA 2009, (S11.005).
39. Yousry, T. A.; Major, E. O.; Ryschkewitsch, C.; Fahle, G.; Fischer, S.; Hou, J.; Curfman, B.; Miszkiel, K.; Mueller-Lenke, N.; Sanchez, E.; Barkhof, F.; Radue, E. W.; Jager, H. R.; Clifford, D. B. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med., 2006, 354 (9), 924-933.
40. Sands, B. K. M.; Bozi, C.; Hamdy, A.; Kouchakji, E.; Hogge, C. Natalizumab use in patients with Crohn's disease and relapsing multiple sclerosis: updated utilization and safety results form the touch prescribing program, the pregnancy registry, and the Inform and Tygris Studies. Gastroenterology, 2009, 136 (Suppl 1), S1044.
41. Erle, D. J.; Briskin, M. J.; Butcher, E. C.; Garcia-Pardo, A.; Lazarovits, A. I.; Tidswell, M. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J. Immunol., 1994, 153 (2), 517-528.
42. Arihiro, S.; Ohtani, H.; Suzuki, M.; Murata, M.; Ejima, C.; Oki, M.; Kinouchi, Y.; Fukushima, K.; Sasaki, I.; Nakamura, S.; Matsumoto, T.; Torii, A.; Toda, G.; Nagura, H. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol. Int., 2002, 52 (5-6), 367-374.
43. Feagan, B. G.; Greenberg, G. R.; Wild, G.; Fedorak, R. N.; Pare, P.; McDonald, J. W.; Dube, R.; Cohen, A.; Steinhart, A. H.; Landau, S.; Aguzzi, R. A.; Fox, I. H.; Vandervoort, M. K. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med., 2005, 352 (24), 2499-2507.
44. Feagan, B. G.; Greenberg, G. R.; Wild, G.; Fedorak, R. N.; Pare, P.; McDonald, J. W.; Cohen, A.; Bitton, A.; Baker, J.; Dube, R.; Landau, S. B.; Vandervoort, M. K.; Parikh, A., Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin. Gastroenterol. Hepatol., 2008, 6 (12), 1370-1377.
45. Bennett, C. F.; Condon, T. P.; Grimm, S.; Chan, H.; Chiang, M. Y. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J. Immunol., 1994, 152 (7), 3530-3540.
46. Schreiber, S.; Nikolaus, S.; Malchow, H.; Kruis, W.; Lochs, H.; Raedler, A.; Hahn, E. G.; Krummenerl, T.; Steinmann, G. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology, 2001, 120 (6), 1339-1346.
47. Yacyshyn, B. R.; Chey, W. Y.; Goff, J.; Salzberg, B.; Baerg, R.; Buchman, A. L.; Tami, J.; Yu, R.; Gibiansky, E.; Shanahan, W. R. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut, 2002, 51 (1), 30-36.
48. van Deventer, S. J.; Tami, J. A.; Wedel, M. K. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut, 2004, 53 (11), 1646-1651.